P. J. Bjorkman

The paper designs SARS-CoV-2 Spike proteins with novel mutations to evaluate vaccine effectiveness against future viral variants using a deep learning model.

A vaccine candidate with polyprotein antigens displayed on nanocages induces neutralizing antibodies to multiple SARS-like coronaviruses.

This study develops a vaccine technology using mRNA encoding spike-EABR to generate eVLPs, enhancing antibody and T-cell responses against SARS-CoV-2 variants.

This study shows that CD4bs immunogens can elicit potent, broad anti-HIV-1 neutralizing antibodies in transgenic and wildtype animals.

The paper tracks changes in SARS-CoV-2 spike protein dynamics across variants using hydrogen/deuterium exchange mass spectrometry, revealing progressive stabilization of the trimer stalk and enhanced NTD dynamics in Omicron BA.1.

This paper characterizes monoclonal antibodies that recognize the CD4-induced open conformation of HIV-1 Env trimers and describes their structural interactions with Env and CD4.

This study identifies cross-reactive monoclonal antibodies against conserved sarbecovirus epitopes using mosaic RBD nanoparticles and shows their neutralization potential against SARS-CoV-2 variants and animal sarbecoviruses.

This study designs mosaic RBD nanoparticles to elicit antibodies against conserved sarbecovirus epitopes, showing broader protection against SARS-CoV-2 variants and animal sarbecoviruses in animal models.

The paper uses cryo-EM to study germline antibody-Env structures to identify key interactions and guide vaccine design.

This paper describes a VRC01-class antibody with lower somatic mutation but comparable breadth and potency to other broadly neutralizing antibodies against HIV-1.

This study identifies two antibodies from immunized macaques that neutralize HIV-1 by targeting the CD4-binding site on an occluded-open Env trimer conformation.

This study identifies an off-target antibody that displaces the HIV-1 Env fusion peptide and blocks neutralizing epitopes, providing insights for vaccine design.

The paper maps mutations in SARS-CoV-2 spike RBD that escape binding by three antibody classes and finds that plasma escape maps closely resemble those of a single antibody class targeting site E484.

This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.

This paper studies the genomic and metabolic interdependence of two recently acquired gammaproteobacterial endosymbionts in mealybugs, showing their rapid adaptation to an intracellular lifestyle.

This study engineers red blood cells to express viral receptors, demonstrating their ability to neutralize HIV-1 and SARS-CoV-2 in vitro.

The paper demonstrates that mosaic nanoparticles displaying multiple coronavirus RBDs induce cross-reactive and neutralizing antibodies against SARS-CoV-2 and zoonotic coronaviruses in mice.

This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.

The paper presents cryo-EM structures of HIV-1 Env trimers bound to CD4-mimetics, showing conformational changes induced by Phe43 pocket binding.

This paper reports a broadly neutralizing monoclonal antibody from a macaque infected with SHIVAD8 that targets the V3-glycan patch of HIV-1 Env, showing neutralizing activity and protective efficacy in vivo.

The paper uses fusion inhibitors to trap HIV-1 in a pre-hairpin intermediate state and visualizes it via electron tomography, revealing the structure of Env-mediated fusion.

This study shows that two Fc-modified monoclonal antibodies limit fetal neurologic damage and vertical transmission of ZIKV in pregnant macaques.

This study constructs and characterizes influenza HA trimer-displaying nanoparticles and evaluates their immunogenicity, finding that mosaic particles do not consistently elicit broader immune responses than homotypic ones.

This paper models synthetic diFabs with DNA linkers to quantify how linker length and rigidity affect antibody neutralization potency against HIV-1.

This study identifies LEM2 and CHMP7 as conserved factors that recruit ESCRT-III proteins to the nuclear envelope during closure in fission yeast and human cells.